5:40 PM
 | 
Jun 13, 2014
 |  BC Extra  |  Clinical News

Karyopharm nearly doubles on Phase I MM data for selinexor

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) jumped $22.77 (94%) to $47.12 on Friday after reporting preliminary data from eight multiple myeloma patients in a Phase I trial of the company's

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >